3 Best Growth Stocks to Buy This Week, According to Analysts – March 16-20

Growth stocks are companies whose sales and earnings are expected to grow faster than the market average, and investors buy them for their future potential rather than current stability. These companies typically reinvest most of their profits back into the business instead of paying dividends, aiming to fund expansion, innovation, and new product development.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

One way to identify these stocks is through their past revenue or earnings growth. Today, we have shortlisted stocks whose revenue has grown at a five-year CAGR of more than 5%. Along with this, we have zeroed in on stocks that have received a “Strong Buy” rating from Wall Street analysts.

Here are this week’s stocks:

Wix WIX -0.15% ▼ – This cloud-based website builder allows individuals and businesses to create and manage professional websites without needing coding skills. WIX stock’s average price target of $133 implies a 51.21% upside potential from the current level. The company’s revenue has grown at a five-year CAGR of 9.4%.

Importantly, TipRanks AI Analyst expects WIX’s revenue to grow by 13.2%, compared with the Technology sector’s average of 8.5%. The company continues to benefit from rising demand for website creation tools, e‑commerce features, and AI‑powered design capabilities.

DoorDash DASH +3.98% ▲ – This on-demand delivery platform connects customers with local restaurants and retailers for food, groceries, and everyday essentials. DASH stock’s average price target of $252.76 implies an upside potential of 50.65%. Its revenue increased at a CAGR of 22.92% in the past five years.

According to TipRanks AI Analyst, DASH’s revenue is expected to grow by 24.46% in comparison to the Consumer Cyclical sector’s average of 1.52%. DoorDash’s growth is being driven by expanding into groceries and retail, rising order frequency, and steady gains in DashPass subscriptions.

Axsome Therapeutics AXSM +1.38% ▲ – This biopharmaceutical company develops and commercializes innovative treatments for central nervous system (CNS) disorders. AXSM stock’s average price target of $221.87 implies an upside potential of 40.22%. The company’s revenue has grown at a five-year CAGR of 13.88%.

The company’s revenue is expected to rise by 65.83%, according to TipRanks AI Analyst. This compares favorably with the Healthcare sector’s average of 22.53%. Axsome’s growth is driven by rising uptake of its depression and migraine drugs, expanding commercial partnerships, and a strong late‑stage pipeline targeting major unmet needs.

Disclaimer & DisclosureReport an Issue